Natco Pharma Limited — Updates, 30-01-2025: Press Release

NATCO Pharma Limited has received approval for its Abbreviated New Drug Application (ANDA) for Everolimus tablets for oral suspension (TFOS), available in 2mg, 3mg, and 5mg dosages. This product, a generic version of Novartis' AFINITOR DISPERZ®, is set to be launched immediately in the U.S. market through marketing partner Breckenridge Pharmaceutical, Inc. The U.S. sales for Everolimus TFOS are estimated at USD 112 million for the 12-month period ending September 2024. This approval represents a significant growth opportunity for NATCO, reaffirming its strategic focus on oncology products and limited competition molecules in the U.S. market. Investors should monitor this development closely, as it could enhance the company's revenue streams and market position in a competitive landscape.